Browse the evidence

The Mediterranean, Dietary Approaches to Stop Hypertension, and vegetarian diets reduce CVD risk.

Health professionals should promote these specific dietary patterns to lower CVD risk.

Tirzepatide administration for 72 weeks elicited significant weight reduction ranging from 5% to 20.9% across different trials in a dose-dependent manner.

Tirzepatide may be an effective option for weight management in patients with obesity and T2DM.

Semaglutide showed the most significant weight reduction among patients with IBD.

Semaglutide may be effective for weight management in IBD patients.

Semaglutide led to a weight reduction of 9.21 kg in the study population.

Semaglutide may assist in significant weight loss for patients in this demographic.

Combined nutrition and exercise interventions significantly reduced body weight by 2.13 kg (95%CI, -3.07 to -1.19) in adults with cancer.

Practitioners can consider combined nutrition and exercise interventions as effective strategies for weight management in cancer patients.

Combined nutrition and exercise interventions significantly reduced fat mass by 2.06 kg (95%CI, -3.02 to -1.09) in adults with cancer.

Practitioners can utilize combined nutrition and exercise interventions to effectively reduce fat mass in cancer patients.

The working group recommends dietary consultations, increased physical activity, resistance training, and potential use of oral nutritional supplements and medications for managing sarcopenic obesity.

Practitioners should consider these recommendations for effective management of sarcopenic obesity.

Resistance-based exercise programs resulted in a significant change of -1.6 kg in whole-body fat mass (95% CI = -1.9 to -1.3 kg, P < 0.001).

Resistance training can effectively reduce body fat in overweight and obese individuals.

Semaglutide has been shown to result in a loss of almost 12% of body weight over a 68-week period.

Semaglutide can be considered an effective option for significant weight loss in eligible patients.

Supplementation with long-chain omega-3 fatty acids and increasing the consumption of alpha-linolenic and linoleic acids in place of saturated fats reduced the risk of coronary events.

Encouraging omega-3 supplementation and specific fatty acid intake may help reduce coronary event risk.

A substantial increase of habitual protein intake above the currently recommended levels is achievable within 17 weeks in community-dwelling older adults.

Practitioners can encourage older adults to increase protein intake significantly above current recommendations.

Body fat mass initially increased, while skeletal muscle mass decreased, but this trend was reversed in the high protein group after resistance training.

Practitioners should note the potential for changes in body composition with high protein intake and resistance training.

GLP-1 agonists reduce food intake and delay gastric emptying, contributing to weight loss.

Understanding these mechanisms can help practitioners better utilize GLP-1 agonists in treatment.

Glucagon coagonists like survodutide and mazdutide have demonstrated significant weight loss and improved glycemic control.

These agents may be effective options for patients needing weight loss and glycemic control.

Physical activity should be included in medical treatments for excess weight and adiposity as deemed medically appropriate.

Practitioners should incorporate physical activity into treatment plans for patients with excess weight.

For weight loss and prevention of weight gain, physical activity should be progressed to at least 150 min·wk −1 of moderate-intensity.

Encourage clients to engage in at least 150 minutes of moderate-intensity physical activity weekly for effective weight management.

Calorie restriction, structured exercise, pharmacotherapy, and metabolic surgeries have shown beneficial effects in reducing VAT.

Implementing these strategies can effectively reduce visceral fat.

Lifestyle preventative approaches, especially combining nutrition and physical activity behavioral components, are essential in preventing multiple long-term conditions.

Practitioners should integrate nutrition and physical activity in prevention strategies.

Innovative exercise prescription should include different intensity-based approaches to target multiple long-term conditions.

Exercise programs should be tailored to individual needs and intensities.

Bariatric surgery is associated with substantial weight reduction (20-30%) and markedly lower subsequent risk for major adverse cardiovascular events (MACE).

Bariatric surgery may be a highly effective option for patients with obesity at risk for cardiovascular events.

After 3 months, average weight loss was 4.11 kg or 4.57%.

Practitioners can expect significant weight loss in patients using semaglutide in a real-world setting.

Individuals lost fat mass (2.67 kg) and trunk fat mass (1.10 kg).

Practitioners can expect reductions in fat mass among patients using semaglutide.

Meal replacement with caloric restriction resulted in greater reductions in body weight and BMI compared to meal replacement without caloric restriction.

Incorporating caloric restriction into meal replacement strategies can enhance weight loss outcomes for T2D patients.

The ELM trial tests the hypothesis that a habit-based lifestyle treatment can produce sustained remission of metabolic syndrome (MetS) at 24 months.

Practitioners may consider implementing habit-based lifestyle interventions for MetS management.